KFP-H020

KFP-H020 is an investigational small molecule inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) being developed by Nanjing Carephar Pharmaceutical, a subsidiary of Jiangsu Carephar Pharmaceutical, for the treatment of hypercholesterolemia. PCSK9 is a key regulator of cholesterol homeostasis that promotes the degradation of low-density lipoprotein receptors (LDLR) on the surface of hepatocytes; by inhibiting PCSK9, KFP-H020 aims to increase LDLR density and enhance the clearance of LDL cholesterol from the blood. In 2022, Nanjing Carephar filed Investigational New Drug (IND) applications for the candidate in both China and the United States. While some reports characterize KFP-H020 as a small interfering RNA (siRNA) therapeutic, the developer's official pipeline documentation identifies it as a small molecule candidate.